Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Circulating microRNAs in association with pancreatic cancer risk within 5 years

ABSTRACT: Circulating microRNAs in association with pancreatic cancer risk within 5 years

PROVIDER: PRJNA1090916 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Circulating microRNAs in association with pancreatic cancer risk within 5 years

Project description:miRNAs levels were measured in plasma samples of pancreatic cancer cases and controls collected within 5 years prior to diagnosis using the NanoString nCounter Human v3 miRNA expression panel

2024-04-01 | GSE262260 | GEO

Analysis of circulating microRNAs in adrenocortical tumours

Project description:Differential diagnosis of adrenocortical adenoma and carcinoma is of pivotal clinical relevance, as the prognosis and clinical management of benign and malignant adrenocortical tumours is entirely different. Circulating microRNAs are promising biomarker candidates of malignancy in several tumours. In the present study we investigate circulating microRNAs in adrenocortical tumours and to evaluate their potential applicability as biomarkers of malignancy.

2013-11-19 | GSE49674 | GEO

Circulating MicroRNAs as Biomarkers of Metabolic Syndrome

Project description:Circulating MicroRNAs as Biomarkers of Metabolic Syndrome

| PRJNA648409 | ENA

Analysis of circulating microRNAs in adrenocortical tumours

2013-11-19 | E-GEOD-49674 | biostudies-arrayexpress

Circulating MicroRNAs and Treatment Response in Childhood Asthma

Project description:Circulating MicroRNAs and Treatment Response in Childhood Asthma

| PRJNA556710 | ENA

Independent validation of circulating microRNAs as biomarkers in a case-control study of adolescents with type 1 diabetes for more than 8 years

Project description:MicroRNAs (miRNAs) are epigenetic regulators of gene activity. Analysis of circulating miRNAs enables minimal-invasive studies of disease mechanisms and identification of novel disease biomarkers. The aim of this case-control validation study was to investigate previously identified circulating miRNAs in Swedish adolescents with long-duration (8.0–16.5 years) type 1 diabetes (T1D), and healthy matched controls to confirm their utility as biomarker candidates to diagnose and monitor the progression of T1D. Quantitative PCR analysis of 23 previously reported miRNAs was performed in 24 T1D and 24 control individuals. Body composition was assessed by dual-energy X-ray absorptiometry and peripheral quantitative computed tomography. Prospectively collected clinical data were retrieved from the Swedish diabetes quality registry. The selected miRNAs showed higher variability in both male and female T1D groups compared to controls. Statistical analysis confirmed differences for 12 miRNAs in comparison with controls, including miR-223-3p and miR-135a-5p, which previously were reported to be associated with T1D. MiR-34a-5p and miR-210-3p were positively associated with T1D duration and HbA1c (average from the last year), respectively. In conclusion, 12 previously reported miRNAs showed consistent differential expression between individuals with T1D and controls. Among these were miR-223-3p and miR-135a-5p, which are associated with cardiovascular/inflammatory disease and cancer, respectively.

2026-02-09 | GSE315292 | GEO

The value of circulating microRNAs for early diagnosis of B-cell lymphoma: A case-control study on historical samples

Project description:MicroRNAs are small regulatory RNAs that are deregulated in a wide variety of human cancers, including different types of B-cell lymphoma. Nevertheless, the feasibility of circulating microRNA for early diagnosis of B-cell lymphoma has not been established. To address the possibility of detecting specific circulating microRNAs years before a B-cell lymphoma is diagnosed, we studied the plasma expression of microRNA first in pre-treatment samples from patients with diffuse large B-cell lymphoma and subsequently in repository samples from blood donors who later developed B-cell lymphomas. In addition, we studied the microRNA expression in the diagnostic lymphoma biopsy and in plasma samples taken after end of treatment. The most strongly induced (miR-326) and suppressed (miR-375) plasma microRNA at diagnosis, when compared with healthy blood donors, were also substantially up- or down-regulated in plasma repository samples taken from several months to up to two years before the blood donors were diagnosed with B-cell lymphoma. Importantly, at these time points the donors had no signs of disease and felt healthy enough to donate blood. In conclusion, this first study of plasma microRNA profiles from apparently healthy individuals, taken several years before B-cell lymphoma diagnosis, suggests that plasma microRNA profiles may be predictive of lymphoma development.

2018-07-14 | GSE117063 | GEO

Circulating microRNAs profile in patients with transthyretin variant amyloidosis

Project description:Circulating microRNAs profile in patients with transthyretin variant amyloidosis

| PRJNA629572 | ENA

Radiation-induced Circulating microRNAs predict cardiac dysfunction after radiotherapy

Project description:Radiation-induced Circulating microRNAs predict cardiac dysfunction after radiotherapy

| PRJNA934403 | ENA

Maternal circulating microRNAs altered in fetal growth restricted pregnancies

Project description:Maternal circulating microRNAs altered in fetal growth restricted pregnancies

| PRJNA777894 | ENA